GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Consensus Recommendation of “Hold” from Brokerages

GoodRx Holdings, Inc. (NASDAQ:GDRXGet Rating) has been given a consensus rating of “Hold” by the twenty brokerages that are covering the company, MarketBeat.com reports. Nine investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $8.31.

Several equities research analysts have issued reports on GDRX shares. Citigroup started coverage on shares of GoodRx in a research note on Thursday, December 1st. They set a “buy” rating and a $7.00 price objective for the company. The Goldman Sachs Group decreased their price objective on shares of GoodRx from $10.00 to $8.00 and set a “neutral” rating for the company in a research note on Wednesday, November 9th. Royal Bank of Canada decreased their price objective on shares of GoodRx from $11.00 to $6.00 and set a “sector perform” rating for the company in a research note on Wednesday, November 9th. DA Davidson reduced their target price on shares of GoodRx to $5.00 in a research report on Tuesday, November 15th. Finally, Morgan Stanley reduced their target price on shares of GoodRx from $10.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 9th.

GoodRx Price Performance

GDRX opened at $5.30 on Friday. The company has a quick ratio of 10.34, a current ratio of 10.34 and a debt-to-equity ratio of 0.83. GoodRx has a 52-week low of $3.82 and a 52-week high of $30.89. The company has a 50 day moving average of $4.94 and a two-hundred day moving average of $5.55. The company has a market cap of $2.10 billion, a P/E ratio of -31.17, a P/E/G ratio of 13.57 and a beta of 0.71.

Institutional Trading of GoodRx

A number of institutional investors and hedge funds have recently modified their holdings of GDRX. Advisor Group Holdings Inc. raised its holdings in shares of GoodRx by 17.6% during the first quarter. Advisor Group Holdings Inc. now owns 28,454 shares of the company’s stock worth $414,000 after purchasing an additional 4,265 shares during the period. Raymond James & Associates raised its holdings in shares of GoodRx by 24.0% during the first quarter. Raymond James & Associates now owns 13,806 shares of the company’s stock worth $267,000 after purchasing an additional 2,675 shares during the period. Citigroup Inc. raised its holdings in shares of GoodRx by 107.6% during the first quarter. Citigroup Inc. now owns 41,084 shares of the company’s stock worth $794,000 after purchasing an additional 21,298 shares during the period. BlackRock Inc. raised its holdings in shares of GoodRx by 5.8% during the first quarter. BlackRock Inc. now owns 1,110,156 shares of the company’s stock worth $21,459,000 after purchasing an additional 60,979 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of GoodRx during the first quarter worth $319,000. 35.22% of the stock is owned by institutional investors and hedge funds.

About GoodRx

(Get Rating)

GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.

Featured Stories

Analyst Recommendations for GoodRx (NASDAQ:GDRX)

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.